ScoreWhy is Theravance Biopharma, Inc. ?
1
With a growth in Net Sales of 15.02%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 268.78 MM
- NET SALES(HY) At USD 63.59 MM has Grown at 86.25%
- ROCE(HY) Highest at 50.17%
2
With ROE of 35.69%, it has a very attractive valuation with a 2.62 Price to Book Value
- Over the past year, while the stock has generated a return of 56.12%, its profits have risen by 304% ; the PEG ratio of the company is 0
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 56.12% in the last 1 year, much higher than market (S&P 500) returns of 25.41%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Theravance Biopharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Theravance Biopharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Theravance Biopharma, Inc.
56.12%
1.93
47.02%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.38%
EBIT Growth (5y)
14.55%
EBIT to Interest (avg)
-10.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.54
Sales to Capital Employed (avg)
0.31
Tax Ratio
20.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
2.62
EV to EBIT
-60.44
EV to EBITDA
-186.17
EV to Capital Employed
20.11
EV to Sales
4.70
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
-33.27%
ROE (Latest)
35.69%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 268.78 MM
NET SALES(HY)
At USD 63.59 MM has Grown at 86.25%
ROCE(HY)
Highest at 50.17%
RAW MATERIAL COST(Y)
Fallen by -0.93% (YoY
CASH AND EQV(HY)
Highest at USD 710.02 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 7.1 times
PRE-TAX PROFIT(Q)
At USD -2.84 MM has Grown at 79.93%
NET PROFIT(Q)
At USD -1.3 MM has Grown at 90.43%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Theravance Biopharma, Inc.
Net Sales
At USD 63.59 MM has Grown at 86.25%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 268.78 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -2.84 MM has Grown at 79.93%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -1.3 MM has Grown at 90.43%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Cash and Eqv
Highest at USD 710.02 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 7.1 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -0.93% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
